Wednesday May 9 10:50am to 11:50am
Describe the similarities and differences among anticoagulants currently available in Canada for stroke prevention in atrial fibrillation (AF).
Communicate the benefits and risks of anticoagulant therapy to patients with AF.
Describe the importance of patient preferences on the selection of anticoagulant therapy in AF.
Recommend appropriate, guideline-recommended anticoagulants at appropriate doses based on patient and drug characteristics.
Use recommended tools to help manage anticoagulation around surgical or invasive procedures.
This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.
This program was supported in part by an educational grant from Servier.
Adam Clarke MD, FRCPC Cardiologist, Internist and Critical Care physician who began working in the Annapolis Valley in 2004. Completed training through Dalhousie University and developed an interest in helping people try and reduce the risk of their first heart attack or stroke rather than meet them afterwards.
Just finished almost 9-years as Chief of Medicine and serves on committees to try and enhance patient care and physician education. Now enjoying helping out with local and provincial organizations aimed at improving physical fitness in children, such as being a board member of Acadia Minor Hockey Association.
Married to Rebecca, a family physician, and has three sons, aged 13, 12 and 5 so if not a work than usually at a rink.
Vikas Kuriachan MD, FRCPC, FHRS, FACC Dr. Vikas Kuriachan joined the Cardiology / Cardiac Electrophysiology group at the Libin Institute and University of Calgary in July 2010 after completing a year of complex ablation training at Brigham and Women’s Hospital / Harvard Medical School. He is currently a Clinical Associate Professor and the program director for the Cardiac Electrophysiology training program. His Cardiology and Cardiac Electrophysiology training were in Calgary and Internal Medicine at University of British Columbia. He was Calgary Avenue Magazine’s Top 40 under 40 in 2013. His clinical and research interests include ablation, in particular VT ablation, device implantation, complex extraction and new electrophysiology technologies.
Theodore Wein MD, FRCPC Dr. Theodore Wein is an assistant professor of neurology and neurosurgery at McGill University. He currently works at the Montreal General Hospital Stroke Prevention Clinic as well as St. Mary's Hospital. Dr. Wein obtained his MD degree at the University Of Vermont College Of Medicine and completed his residency in neurology at McGill University. He subsequently completed a 2 year fellowship in cerebrovascular disease at the University of Texas – Houston as well as a neuromuscular fellowship in the department of neurology and physical medicine at the University of Michigan. In addition to active interest in acute stroke care as well secondary stroke prevention, Dr. Wein is actively involved in post stroke rehabilitation. He is the past chairman of the spasticity section of the Canadian Botulinum Toxin Conference and is on the steering committee of several ongoing trials looking at the effectivess of Botulinum toxin on spasticity. Dr. Wein is a fellow of the American Heart Association Stroke Council and serves on the Board of Directors of the Canadian Stroke Consortium. He is actively involved in stroke related clinical trials. Dr. Wein is the Chair of the American heart association International Stroke Conference pre-symposium and for the past 3 years has co chaired the SSVQ's Sommet sur L'AVC. This year Dr. Wein is also the chairman of the Quebec Heart and Stroke Foundations annual Sommet Pour Vaincre L'AVC.